SPAM1 and neoplasm: Since, PH20 HYAL has a short half-life, a pegylated recombinant human PH20 variant (PEGPH20) can remodel the stroma of HA-rich tumors by improving the intra-tumor distribution of anticancer drugs and enhancing their therapeutic efficacy without increasing toxicity [24,25,26].